Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

101. Evaluation of walking exercise on glycemic control in patients with type 2 diabetes mellitus: a protocol for systematic review and meta analysis of randomized cross-over controlled trials Full Text available with Trip Pro

Evaluation of walking exercise on glycemic control in patients with type 2 diabetes mellitus: a protocol for systematic review and meta analysis of randomized cross-over controlled trials Inplasy Protocol 774 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

102. Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis Full Text available with Trip Pro

Daigaku Hiromichi Wakui Yokohama City University Graduate School of Medicine Corresponding Author Kouichi Tamura Yokohama Shiritsu Daigaku DOI: License: This work is licensed under a CC BY 4.0 License. View the published version . Abstract Background Both sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to reduce cardiovascular and renal events in type 2 diabetes mellitus (DM) patients. However, no study to date has compared (...) PDF Downloads : ... HTML Views : ... Subject Areas Subject Areas DOI & PDF DOI: License License: This work is licensed under a CC BY 4.0 License. Declarations View the published version . Abstract Background Both sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to reduce cardiovascular and renal events in type 2 diabetes mellitus (DM) patients. However, no study to date has compared the effect of SGLT-2 inhibitors

2020 Research Square

103. Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis

Evidenced-Based Medicine Reviews, CINAHL, Embase, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, PROSPERO, PsycInfo, PubMed, and Web of Science until 24 April 2019. Study selection: We included randomized controlled trials ≥2 weeks' duration comparing technologies for management of type 1 diabetes in adults (≥18 years of age), excluding pregnant women. Data extraction: Data were extracted using a predefined template. Outcomes were percent time with sensor glucose levels 3.9-10.0 mmol/L (70 (...) Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest

2020 EvidenceUpdates

104. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) Full Text available with Trip Pro

Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) - PubMed This site needs JavaScript (...) Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Sep;43(9):2025-2033. doi: 10.2337/dc20-0408. Epub 2020 Jul 13. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) , , , , , , , , , , Affiliations Expand Affiliations 1 Steno Diabetes Center

2020 EvidenceUpdates

105. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial Full Text available with Trip Pro

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial - PubMed This site needs JavaScript to work properly (...) Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul 21;dc192316. doi: 10.2337/dc19-2316. Online ahead of print. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial , , , , , , , , Affiliations Expand Affiliations 1 Dallas Diabetes Research Center at Medical City

2020 EvidenceUpdates

106. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2

Metab Actions . 2020 Jul 3. doi: 10.1111/dom.14127. Online ahead of print. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 , , , , , , , Affiliations Expand Affiliations 1 Endocrine and Metabolic Consultants, Rockville, Maryland, USA. 2 Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. 3 Diabetes Centers of America-Dallas (...) Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History

2020 EvidenceUpdates

107. Semaglutide (Rybelsus) - For the treatment of adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control as an adjunct to diet and exercise

Semaglutide (Rybelsus) - For the treatment of adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control as an adjunct to diet and exercise 1 Published 7 September 2020 Product update SMC2287 semaglutide 3mg, 7mg and 14mg tablets (Rybelsus®) Novo Nordisk 7 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs (...) ) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following assessment under the abbreviated process semaglutide (Rybelsus®) is accepted for restricted use within NHSScotland. Indication under review: for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise ? As monotherapy when metformin is considered inappropriate due to intolerance or contraindications ? In combination with other

2020 Scottish Medicines Consortium

108. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison Full Text available with Trip Pro

Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison - PubMed This site needs JavaScript to work properly. Please enable (...) options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Jul 6. doi: 10.1111/dom.14136. Online ahead of print. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison , , , , , , , , Affiliations Expand Affiliations 1 Translational and Clinical Research Institute, Newcastle University, Newcastle upon

2020 EvidenceUpdates

109. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study

Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul 28;dc200736. doi: 10.2337/dc20-0736. Online ahead of print. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA 1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study , , , , , , , Affiliations Expand Affiliations 1 Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K. hood.thabit@mft.nhs.uk. 2 Division of Diabetes (...) Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study Hood Thabit et al. Diabetes Care . 2020 . Show details Display options Display options Format Diabetes Care Actions . 2020 Jul 28;dc200736. doi: 10.2337/dc20-0736. Online ahead of print. Authors , , , , , , , Affiliations 1 Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K. hood.thabit@mft.nhs.uk. 2 Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health

2020 EvidenceUpdates

110. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study Full Text available with Trip Pro

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Aug 14;dc201104. doi: 10.2337/dc20-1104. Online ahead of print. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

111. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. (Abstract)

Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. The American Diabetes Association (ADA) updates the Standards of Medical Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of diabetes.To develop the 2020 Standards, the ADA Professional (...) Practice Committee, comprising physicians, adult and pediatric endocrinologists, diabetes educators, registered dietitians, epidemiologists, pharmacists, and public health experts, continuously searched MEDLINE (English language only) from 15 October 2018 through August-September 2019 for pertinent studies, including high-quality trials that addressed pharmacologic management of type 2 diabetes. The committee selected and reviewed the studies, developed the recommendations, and solicited feedback from

2020 Annals of Internal Medicine

114. The impact of sleep duration and sleep quality on glycaemic control in Asian population with type 2 diabetes mellitus: A systematic literature review and meta-analysis of observational studies Full Text available with Trip Pro

The impact of sleep duration and sleep quality on glycaemic control in Asian population with type 2 diabetes mellitus: A systematic literature review and meta-analysis of observational studies Redirecting

2020 Clinical epidemiology and global health

115. Comparative efficacy and safety of traditional Chinese patent medicine for the treatment of type 2 diabetes mellitus: A Bayesian network meta-analysis protocol Full Text available with Trip Pro

Comparative efficacy and safety of traditional Chinese patent medicine for the treatment of type 2 diabetes mellitus: A Bayesian network meta-analysis protocol Inplasy Protocol 723 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

116. Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials Full Text available with Trip Pro

Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials Inplasy Protocol 720 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

117. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. (Abstract)

A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes.In a 16-week, multicenter, randomized, open-label, parallel-group trial, we assigned, in a 3:1 ratio, children 6 to 13 years of age who had type 1 diabetes to receive treatment with the use of either a closed-loop system of insulin delivery (closed-loop group) or a sensor-augmented (...) that the system was in the closed-loop mode was 93% (interquartile range, 91 to 95). No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either group.In this 16-week trial involving children with type 1 diabetes, the glucose level was in the target range for a greater percentage of time with the use of a closed-loop system than with the use of a sensor-augmented insulin pump. (Funded by Tandem Diabetes Care and the National Institute of Diabetes and Digestive and Kidney Diseases

2020 NEJM

118. Weight maintenance interventions for people with type 2 diabetes mellitus: A systematic review protocol Full Text available with Trip Pro

Weight maintenance interventions for people with type 2 diabetes mellitus: A systematic review protocol Weight maintenance interventions for people with type 2 diabetes mellitus: A systematic review protocol | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting (...) of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Protocol Weight maintenance interventions for people with type 2 diabetes mellitus: A systematic review protocol Sarah Sauchelli, Julia Bradley, Jennifer Cox, Clare England, Rachel Perry Sarah Sauchelli NIHR Bristol Biomedical Research Centre (Nutrition Theme) Corresponding Author ORCiD: https://orcid.org/0000-0003-3620-7671

2020 Research Square

119. Prevalence and Risk Factors of Depression in Chinese Patients With Type 2 Diabetes Mellitus: a Protocol of Systematic Review and Meta-analysis Full Text available with Trip Pro

Prevalence and Risk Factors of Depression in Chinese Patients With Type 2 Diabetes Mellitus: a Protocol of Systematic Review and Meta-analysis Prevalence and Risk Factors of Depression in Chinese Patients With Type 2 Diabetes Mellitus: a Protocol of Systematic Review and Meta-analysis | Research Square Browse Tools & Services Your Cart This preprint is under consideration at Systematic Reviews . A preprint is a preliminary version of a manuscript that has not completed peer review at a journal (...) . Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Protocol Prevalence and Risk Factors of Depression in Chinese Patients With Type 2 Diabetes Mellitus: a Protocol of Systematic Review and Meta-analysis Xiaobo LIU, Chao Dong, Hong Jiang, Dongling Zhong, Yuxi Li, Huiling Zhang, Jun Zhang

2020 Research Square

120. Weight maintenance interventions for people with type 2 diabetes mellitus: A systematic review protocol Full Text available with Trip Pro

Weight maintenance interventions for people with type 2 diabetes mellitus: A systematic review protocol Weight maintenance interventions for people with type 2 diabetes mellitus: A systematic review protocol | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting (...) of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Protocol Weight maintenance interventions for people with type 2 diabetes mellitus: A systematic review protocol Sarah Sauchelli, Julia Bradley, Jennifer Cox, Clare England, Rachel Perry Sarah Sauchelli NIHR Bristol Biomedical Research Centre (Nutrition Theme) Corresponding Author ORCiD: https://orcid.org/0000-0003-3620-7671

2020 Research Square